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Abstract: One of the major problems met for the conception of antiviral or antiparasitic drugs is to
reach a high level of selectivity towards the pathogenic agent versus the host. We shall describe
two synthetic approaches where main group organometallics have been used towards this goal. A
series of nucleoside sila-analogues was synthesized as potential therapeutic agents designed to
inhibit HIV Reverse Transcriptase. In a second approach novel organosilicon derivatives have
been synthesized as mimics of antisense oligonucleotides.
Infectious agents, namely viruses or parasites, more or less use cellular machinery. Therefore
therapeutic agents must interfere with biochemical mechanisms or possess high affinity towards
specific molecular cellular components, to reach selectivity.
We thought that main group organometallics could show many advantages for designing
biologically active molecules in this field. They allow a high synthetic flexibility for the modulations
of physico-chemical properties and they show a mechanistic behaviour which may be close to the
one of several heteroelements present in living organisms such as sulfur or phosphorus.
We tried to use this approach towards two directions involving the synthesis of organosilicon
derivatives i.e"
-the synthesis of organosilicon derivatives as inhibitors of HIV Reverse Transcriptase,
-the synthesis of organosilicon precursors of modified antisense oligonucleotides.
1- Organosilicon Derivatives as Potential Inhibitors of HIV Reverse Transcriptase.
This enzyme is one of the most important targets (1) for the development of antiretrovirals against
HIV. It catalyses the RNA directed synthesis of viral DNA (DNA pol activity) and in a second step
the degradation of the RNA/DNA double strand (RNase H activity). Most of the RT inhibitors so
far approved for clinical use, as for example AZT or D4T (2)(scheme 1), are not actual RT
inhibitors but DNA chain elongation terminators. Other classes of inhibitors have been
developped, as HEPT or TIBO and others (3). These ones are no longer DNA chain elongation
inhibitors but they interact with a non catalytic site within the enzyme.
AZT dT HEPT
TIBO
Scheme
k Conference given in ICEBAMO 94 (International Conference on Environmental
and Biological Aspects of Main-Group Organometals, Bordeaux 06-09/09/94).
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Thus any mutation of this protein lowers their affinity without affecting catalytic potency.
We tried to imagine structures of potential inhibitors from the biochemical mechanism of DNA
polymerase which is shown on scheme 2. On this scheme is shown the nucleophilic attack of the
last grafted nucleotide on the -phosphorus of the nucleotide which will be next linked, with
expulsion of the diphosphate moiety which is in apical position.
So we decided to synthesize either monosubstrate- or disubstrate-analogues, examples of which
are shown on scheme 3a,3b.
Scheme 2
N-XN-.J
!
Scheme 3
The synthesis of monosubstrate analogues was performed with thymine and adenine as bases. It
required an hydrosilylation reaction (4) of the allyl base as shown on scheme 4. Yields were low,
12% for thymine and 25% for adenine, due to difficulties encountered for compound purification.
o H2PtCI6
NH
NHIN
Br 1
HSiCIPhCH3
H2PtCI6
Scheme 4
Bisubstraie nalogues was synthesize6 following two ways.
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The first one is shown on scheme 5. It requires the condensation of thymine, adenine or of an
heterocyclic sodium salt on chloropropyl-dimethyl chlorosilane followed by hydrolysis (or on the
corresponding disiloxane). Results are gathered in table 1. For thymine and adenine we could
obtain mixtures or regio-isomers which were separated.
CI-SiCI
HetNa/DMSO et
--(CH2)n]
Scheme 5
Heterocycle
o
0
NH2
NH
0
OLi-(CH,)n_l
H2N
oti-(CH)n_.J 2
Products
o
(CH,)n.,Si-O-Si-(CH,)n
/
oE(CH=)] 2
"(CH2)312
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"(CH2)3] 2
(CH2)a] 2 oEi
Yield (%)
18
40
59
47
21
27
Table I
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The second synthetic way was acylation reaction of bis-aminopropyltetramethyldisiloxane with
isatoic anhydrides from which we obtained orthoamino benzamides (Yields 65-95%). These ones
were then cyclized and reduced to quinazoline derivatives (Yields ca 60%)(scheme 6).
o o
R O NH(CHa)--- O II / + O -(CH2)-
NH2
""N O "NH 2
R’ R’
R=H,CI
R’= H,Me
O O
(CH)-- O
[I L NJ
2
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Scheme 6
The synthesized compounds were tested in IBGC CNRS Bordeaux (Dr S.Litvak ), for their activity
as inhibitors of recombinent HIV RT, with poly-rA oligodT as template for catalytic activity. Most of
them did not show any significant activity. Only compounds 132, 82b and 91 showed activities
which ranged from IC5o=20 to 125 Im and could be compared with TIBO activity, i.e 60 IM in the
same model. More accurate analyses were performed (scheme 7). RNase H activity was found to
be much less affected than RNA directed-DNA polymerase activity as well by compound 132 as by
compound 82B (scheme 9). In every case IC50 inhibitory concentrations were shown to be
respectively 20 and 60m and cellular DNA (-polymerase was not affected by these compounds
till 5O0 M.
lOO
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Scheme 7
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The activity of the synthesized compounds has been studied on cultures of HIV-1 infected MT2
cells for their antiretroviral properties, and uninfected for their cytotoxic activities, in the
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Laboratoire de Virologie Humaine, Universit6 de Bordeaux II (Pr H. Fleury). Results, presented on
scheme 8, highlight that most of these compounds show either a high cytotoxicity (low CD50 with
good antiretroviral properties or a low activity (high ID50). Only compound 82b exhibits a good
ratio between its antiretroviral activity (ID50 12 M) and its cytotoxicity on uninfected MT2 cells
(CD50 > 100 M).
2O III
CD 50 (IJM)
r-1 ID 50 (IJM)
81 133 62 95 85 103123 39 63 91 132 92 82b87 134 88 11382a 99 106AZT
Scheme 8
As this compound had been designed not to be an AZT-like DNA elongation terminator, it was
studied for its antiretroviral properties on AZT-susceptible (BGL) and AZT-resistent (BRG) clinical
isolates of HIV-1 obtained from a patient prior to and following initiation of AZT therapy. Close
levels of activity were observed for both strains (IC50 13 IM, Scheme 9).
125
100 .B----
0,1 1,0 10,0
JLA 82b (jaM)
100,0
BGL,e BRG
Scheme 9
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2- Organosilicon precursors of modified antisense oligonucleotides.
Antisense approach deals(5,6) with the synthesis of oligonucleotides complementary of either DNA
or RNA sequences. This complementarity, which confers a very high selectivity to the
base-pairing, allows to block either transcription if the target is DNA or translation if the target is
m-RNA (7,8). Thus one has to synthesize oligonucleotides the length of which most often vary
from 13 to 20 nucleotides (9).
These antisense nucleotides, if not modified, suffer from several limitations"
-they undergo rapid enzymatic degradation by nucleases,
-they offer a poor cellular penetration,
-they only afford a narrow range for the modulation of their physico-chemical properties
-they present a lot of difficulties arising from deoxyribose chemistry (10).
In order to overcome these difficulties, modifications have been introduced within the structure of
antisense oligonucleotides, mainly dealing with the modification of the phosphodiester linkage,
synthesis of phosphorothioates, or phosphonates (1 and 2 Scheme 10).
Scheme 10
We underwent the synthesis of organosilicon precursors of modified oligonucleotides. The
chemical target was chosen (shown on scheme 11) such as ribose is replaced by a linear chain
which bears two hydroxy functions in pseudo-3’ and pseudo-5’ positions, and a silicon atom on the
pseudo-4’ position.
Silicon atom is linked to one chain which embodies a three carbon linker and a nucleic base. The
fourth valence remaining on silicon is variable and could allow modulations of the physico-
chemical properties of the molecule.
OH
L
Base
ON
Scheme 11
B B= B
0 0 0
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Scheme 12
The final goal is the insertion of this monomeric unit within an oligonucleotide in order to obtain
antisense oligodeoxynucleotides (Scheme 12).
The synthesis of the monomers was performed with thymine and adenine as the nucleic bases.
Hydrosilylation of allyl-substituted bases being the key step for introducing a silicon atom on the
structure, hydrogenosilanes were first synthesized by reduction of the corresponding chlorosilane
as shown on scheme 13.
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Scheme 13
Then was performed the synthesis of the thymine monomer as shown on scheme 14. The process
required allylation of bis-trimethylsilyl protected thymine, followed by hydrosilylation, acetoxylation
of the chloromethyl moiety, and subsequent saponification which yielded respectively alcohol or
diol( overall yield 5% and 13%).
0 O
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Br NH N"H
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M%SiO O
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O O
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Scheme 14
As hydrosilylation, when performed on allyl-adenine, gave very poor yields (ca 3%), even after
protection, we started from the readily available 6-chloropurine (Scheme 15). Its sodium salt was
allylated with allyl bromide (65%).
cI NH
AcONa, DMF N N\, NH MeOH
N -= N
Ac O---X /-,,, HO--- //J
Si Si
/ "R / "R
R CH, CH=CI
Scheme 15
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Subsequent hydrosilylation, yielded organosilicon derivatives (yield= 57% R= CH2Cland 17%
R=Me). Then acetoxylation (66%) and reaction with methanolic ammonia (65% and 50%) yielded
desired adenyl derivatives.
Thymine monomer was protected as 4,4’-dimethoxytrityl ether and then reacted with commercial
diisopropyl,I]-cyanoethoxy chlorophosphoramidite, as shown on scheme 16, in collaboration, by Dr
S. Moreau (INSERM U386, Bordeaux).
O
HO\ 0
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DMTCI
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O
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Scheme 16
So was obtained a sila-analogue of a nucleotide including both protective and activating groups
which allow its use in solid phase oligonucleotide synthesis on an automatic synthesizer. This
monomer was incorporated within a 17mer deoxyoligonucleotide complementary of a part of the
coding sequence for rabbit I]-globin:
5’-TT GTG ST_.CA AAA GCA AGT-3’.
Studies to determine the influence of this substitution on the physico-chemical properties of base
pairing (Tin) are currently underway.
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